文献速递胸部肿瘤

PD-L1表达与EGFR突变肺腺癌TKI治疗疗效及免疫微环境的关系

Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
PubMed 文献 · Eur J Cancer · 2019-11-21

该回顾性研究对153例接受EGFR-TKI治疗的晚期EGFR突变肺腺癌患者进行PD-L1免疫组化检测,发现PD-L1<50%者客观缓解率和无进展生存期更优,且PD-L1高表达者继发T790M突变比例更低,提示PD-L1与TKI疗效及耐药模式相关。

要点

  • PD-L1<50%者EGFR-TKI的ORR和PFS更优,≥50%者PFS仅5.9个月。
  • PD-L1<50%是更长PFS的独立预后因素(HR 0.433)。
  • PD-L1高表达者继发T790M突变比例更低(≥50%者仅10%)。

核心结论

  • 治疗前PD-L1较低与EGFR-TKI治疗后更好的ORR、更长的PFS及更高的T790M耐药突变频率相关。

研究设计与样本

  • 回顾性研究,采用Dako 22C3免疫组化检测153例晚期EGFR突变肺腺癌患者治疗前肿瘤PD-L1表达,所有患者均接受TKI治疗。
  • 对15例样本应用多重免疫组化探索肿瘤微环境中的免疫细胞。

主要发现

  • PD-L1 0%、1-49%、≥50%三组的ORR分别为65.6%、56.4%、38.9%,PFS分别为12.5、12.8、5.9个月(P<0.05)。
  • 多因素分析显示PD-L1<50%是更长PFS的独立预后因素(HR 0.433,95%CI 0.250-0.751,P=0.003)。
  • PD-L1 0%、1-49%、≥50%三组继发T790M突变比例分别为53.7%、35.7%、10%(P=0.024)。
  • 15例多重免疫组化提示PD-L1、免疫细胞与EGFR-TKI应答之间存在潜在相关性。

关键数值与推荐

  • PD-L1表达以<50%为界与更好的ORR和PFS相关。
  • PD-L1≥50%者继发T790M突变比例仅10%,低于PD-L1 0%者的53.7%。

临床怎么用

  • 治疗前PD-L1检测可能有助于预判EGFR突变肺腺癌患者TKI疗效及继发T790M耐药风险。
  • PD-L1高表达患者TKI疗效可能较差且T790M耐药比例低,需关注其他耐药机制。

局限性

  • 回顾性研究,样本为台湾地区人群,结论外推需谨慎。
  • 多重免疫组化仅检测15例,微环境分析证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Besides being a predictive biomarker of response to immunotherapy in lung cancer in general, programmed death-ligand 1 (PD-L1) is not so well correlated with treatment outcomes of lung adenocarcinoma (ADC) harbouring epidermal growth factor receptor (EGFR) mutations, as reported studies are inconclusive and seldom addressed the issues of response to treatment and resistance. The primary objective is to evaluate the association of PD-L1 and EGFR tyrosine kinase inhibitor (TKI) efficacy, resistance, and relevant clinical outcomes. The secondary objective is to further explore the tumour microenvironments of EGFR mutant tumours with different PD-L1 expression. METHODS AND MATERIALS: Using immunohistochemical (IHC) staining, we retrospectively tested PD-L1 expression (Dako 22C3) in the pre-treatment tumours from advanced EGFR mutant lung ADC patients, of whom all were treated with TKIs. Multiplex IHC assay was applied for exploring immune cells in tumour microenvironments. RESULTS: A total of 153 Taiwanese patients were enrolled in our study, of whom a majority of cases were female (58.9%) and non-smokers (75.8%). The objective response rate (ORR) to EGFR TKI and progression-free survival (PFS) were better in patients with PD-L1 expression <50% (ORR/PFS in PD-L1 0% versus 1-49% versus ≥50%: 65.6%/12.5 months versus 56.4%/12.8 months versus 38.9%/5.9 months, P < 0.05). The multivariate analysis showed that PD-L1 <50% was an independent prognostic factor for longer PFS (hazard ratio (HR) 0.433, 95% confidence interval (CI) 0.250-0.751, P = 0.003). Furthermore, tumours with higher PD-L1 expression were less likely to develop a secondary T790M mutation (T790M+ in PD-L1 0% versus 1-49% versus ≥50%: 53.7% versus 35.7% versus 10%, P = 0.024). Multiplex IHC tests were applied in 15 cases and revealed a potential correlation between PD-L1, immune cells, and EGFR TKI responses. CONCLUSIONS: Lower pre-treatment PD-L1 is associated with better ORR, PFS, and higher frequency of T790M resistance in EGFR TKI-treated lung ADC patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Yang CY, Liao WY, Ho CC, et al. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. Eur J Cancer. 2019. PMID: 31760310. doi:10.1016/j.ejca.2019.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。